Phathom Pharmaceuticals, Inc. (PHAT) Guidance & Earnings Results
On 2026-07-30 Phathom Pharmaceuticals, Inc. issued guidance: "FY2026 gross-to-net discount 55-59%; gross margin…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PHATPhathom Pharmaceuticals, Inc.Follow PHAT — free
—
Price chart with a free account
- Market cap
- 464.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 30 Jul 26 | — | FY2026 gross-to-net discount 55-59%; gross margin ~80% · full year |
| 30 Apr 26 | Reaffirmed | FY2026 net revenue $320-$345M; non-GAAP op ex $235-$255M · full year |
| 26 Feb 26 | Raised | Operating profitability expected beginning Q3 2026 and for FY2026; cash flow positivity in 2027 · full year |
| 7 Jan 26 | Raised | Operating profitability expected H2 2026 |
| 30 Oct 25 | Raised | Revenue guidance raised to $170-$175M from prior · full year |
| 7 Aug 25 | Raised | FY2025 revenue $165-175M (prior not explicitly stated but implied raise from earlier guidance); Q3 non-GAAP op ex <$60M; Q4 non-GAAP op ex <$55M · full year |
Phathom Pharmaceuticals, Inc. — questions
- What guidance did Phathom Pharmaceuticals, Inc. give?
- On 2026-07-30: "FY2026 gross-to-net discount 55-59%; gross margin ~80%"
- When does Phathom Pharmaceuticals, Inc. report earnings?
- Phathom Pharmaceuticals, Inc.'s next earnings report is expected on 2026-10-29.
Every figure on this page comes from Phathom Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.